| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Sympathetic Nervous System | 17 | 2019 | 111 | 7.30 | Why? |
| Hypertension | 77 | 2021 | 8895 | 6.79 | Why? |
| Blood Pressure | 53 | 2019 | 2198 | 5.83 | Why? |
| Antihypertensive Agents | 25 | 2021 | 1962 | 3.99 | Why? |
| Blood Pressure Monitoring, Ambulatory | 21 | 2019 | 341 | 2.97 | Why? |
| Baroreflex | 5 | 2019 | 54 | 2.37 | Why? |
| Blood Pressure Determination | 11 | 2018 | 450 | 2.27 | Why? |
| Uric Acid | 6 | 2019 | 285 | 2.16 | Why? |
| Hypertrophy, Left Ventricular | 10 | 2019 | 219 | 2.10 | Why? |
| Metabolic Syndrome | 7 | 2018 | 810 | 1.58 | Why? |
| Heart Rate | 11 | 2019 | 1527 | 1.56 | Why? |
| Essential Hypertension | 2 | 2018 | 48 | 1.42 | Why? |
| Vascular Stiffness | 5 | 2019 | 264 | 1.38 | Why? |
| Carotid Intima-Media Thickness | 7 | 2018 | 179 | 1.35 | Why? |
| Cardiovascular Diseases | 21 | 2021 | 11497 | 1.25 | Why? |
| Prediabetic State | 2 | 2018 | 200 | 1.20 | Why? |
| Ventricular Function, Left | 7 | 2019 | 1555 | 1.18 | Why? |
| Norepinephrine | 5 | 2019 | 152 | 1.13 | Why? |
| Sympathectomy | 5 | 2019 | 67 | 1.13 | Why? |
| Ventricular Dysfunction, Left | 5 | 2019 | 993 | 1.09 | Why? |
| Insulin Resistance | 4 | 2019 | 669 | 1.06 | Why? |
| Muscle, Skeletal | 5 | 2019 | 915 | 1.04 | Why? |
| Pulse Wave Analysis | 6 | 2019 | 221 | 0.97 | Why? |
| White Coat Hypertension | 3 | 2018 | 24 | 0.95 | Why? |
| Echocardiography | 19 | 2019 | 3661 | 0.92 | Why? |
| Atrial Function, Left | 2 | 2019 | 82 | 0.85 | Why? |
| Arterial Pressure | 2 | 2021 | 208 | 0.81 | Why? |
| Autonomic Pathways | 2 | 2018 | 8 | 0.81 | Why? |
| Atenolol | 1 | 2019 | 7 | 0.81 | Why? |
| Hyperuricemia | 2 | 2017 | 160 | 0.80 | Why? |
| Retinal Vessels | 2 | 2017 | 255 | 0.79 | Why? |
| Heart Failure | 8 | 2021 | 6638 | 0.78 | Why? |
| Dihydropyridines | 1 | 2019 | 29 | 0.78 | Why? |
| Efferent Pathways | 1 | 2018 | 4 | 0.76 | Why? |
| Heart Ventricles | 8 | 2019 | 1139 | 0.76 | Why? |
| Biological Variation, Population | 1 | 2018 | 69 | 0.73 | Why? |
| Metoprolol | 1 | 2018 | 42 | 0.73 | Why? |
| Atrial Function, Right | 1 | 2018 | 13 | 0.73 | Why? |
| Ventricular Function, Right | 3 | 2019 | 388 | 0.72 | Why? |
| Renin-Angiotensin System | 6 | 2021 | 3661 | 0.72 | Why? |
| Muscle Contraction | 1 | 2018 | 60 | 0.72 | Why? |
| Ventricular Remodeling | 3 | 2019 | 349 | 0.71 | Why? |
| Neural Pathways | 1 | 2019 | 155 | 0.71 | Why? |
| Carotid Artery Diseases | 5 | 2019 | 251 | 0.71 | Why? |
| Stress, Mechanical | 1 | 2018 | 143 | 0.71 | Why? |
| Triglycerides | 2 | 2018 | 478 | 0.69 | Why? |
| Obesity | 8 | 2021 | 7388 | 0.69 | Why? |
| Adrenergic beta-Antagonists | 2 | 2019 | 465 | 0.68 | Why? |
| Nebivolol | 1 | 2016 | 12 | 0.68 | Why? |
| Sodium-Glucose Transporter 2 | 1 | 2017 | 111 | 0.67 | Why? |
| Hydrochlorothiazide | 1 | 2016 | 31 | 0.66 | Why? |
| Adamantane | 1 | 2017 | 68 | 0.65 | Why? |
| Vasoconstriction | 1 | 2018 | 153 | 0.65 | Why? |
| Circadian Rhythm | 5 | 2019 | 607 | 0.65 | Why? |
| Dipeptides | 1 | 2017 | 106 | 0.63 | Why? |
| Glucose Intolerance | 1 | 2017 | 115 | 0.62 | Why? |
| Electric Stimulation Therapy | 1 | 2017 | 151 | 0.60 | Why? |
| Diabetes Mellitus, Type 2 | 7 | 2019 | 6166 | 0.60 | Why? |
| Diabetic Angiopathies | 1 | 2017 | 146 | 0.58 | Why? |
| Biphenyl Compounds | 1 | 2016 | 249 | 0.58 | Why? |
| Prehypertension | 3 | 2019 | 14 | 0.58 | Why? |
| Drug Therapy, Combination | 6 | 2019 | 7268 | 0.57 | Why? |
| Masked Hypertension | 3 | 2019 | 15 | 0.57 | Why? |
| Granulomatosis with Polyangiitis | 1 | 2017 | 161 | 0.55 | Why? |
| Hemoptysis | 1 | 2017 | 172 | 0.55 | Why? |
| Tetrazoles | 1 | 2016 | 262 | 0.53 | Why? |
| Stroke Volume | 5 | 2019 | 2153 | 0.51 | Why? |
| Receptors, Adrenergic, beta | 1 | 2012 | 19 | 0.51 | Why? |
| Cognition Disorders | 1 | 2018 | 574 | 0.50 | Why? |
| Kidney | 7 | 2019 | 3648 | 0.50 | Why? |
| Retina | 1 | 2017 | 424 | 0.48 | Why? |
| Carotid Arteries | 3 | 2018 | 182 | 0.47 | Why? |
| Angiotensin Receptor Antagonists | 5 | 2021 | 3892 | 0.46 | Why? |
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2017 | 436 | 0.46 | Why? |
| Hypoglycemic Agents | 4 | 2017 | 2165 | 0.46 | Why? |
| Independent Living | 1 | 2018 | 842 | 0.45 | Why? |
| Body Mass Index | 4 | 2019 | 4306 | 0.45 | Why? |
| Humans | 119 | 2021 | 930598 | 0.43 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2021 | 5277 | 0.42 | Why? |
| Recovery of Function | 2 | 2017 | 2461 | 0.41 | Why? |
| Muscles | 3 | 2019 | 152 | 0.40 | Why? |
| Denervation | 3 | 2019 | 26 | 0.40 | Why? |
| Cognition | 1 | 2018 | 1394 | 0.38 | Why? |
| Cardiovascular System | 2 | 2019 | 750 | 0.38 | Why? |
| Vascular Diseases | 1 | 2018 | 846 | 0.38 | Why? |
| Endothelium, Vascular | 2 | 2017 | 1751 | 0.37 | Why? |
| Predictive Value of Tests | 9 | 2020 | 9537 | 0.36 | Why? |
| Renal Insufficiency, Chronic | 4 | 2021 | 2654 | 0.35 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.35 | Why? |
| Frail Elderly | 1 | 2017 | 1427 | 0.35 | Why? |
| Coronary Disease | 3 | 2019 | 645 | 0.34 | Why? |
| Case-Control Studies | 12 | 2019 | 17671 | 0.34 | Why? |
| Hypertension, Malignant | 1 | 2006 | 3 | 0.33 | Why? |
| Middle Aged | 54 | 2021 | 270681 | 0.33 | Why? |
| Sleep Wake Disorders | 1 | 2018 | 1463 | 0.32 | Why? |
| Aortic Valve Stenosis | 3 | 2019 | 741 | 0.32 | Why? |
| Male | 63 | 2021 | 367725 | 0.31 | Why? |
| Cold Temperature | 1 | 2008 | 260 | 0.31 | Why? |
| Microcirculation | 3 | 2018 | 447 | 0.31 | Why? |
| Heart Atria | 3 | 2019 | 267 | 0.31 | Why? |
| Drug Resistance | 2 | 2019 | 395 | 0.30 | Why? |
| Hypotension | 2 | 2019 | 392 | 0.29 | Why? |
| Italy | 23 | 2021 | 38444 | 0.29 | Why? |
| Heart | 4 | 2018 | 1791 | 0.29 | Why? |
| Life Style | 6 | 2021 | 2708 | 0.28 | Why? |
| Female | 54 | 2021 | 380317 | 0.27 | Why? |
| Arthritis, Rheumatoid | 1 | 2018 | 2043 | 0.27 | Why? |
| Reference Values | 3 | 2019 | 795 | 0.26 | Why? |
| Acute Coronary Syndrome | 1 | 2017 | 2107 | 0.26 | Why? |
| Hemodynamics | 4 | 2019 | 1562 | 0.26 | Why? |
| Societies, Medical | 6 | 2020 | 6907 | 0.26 | Why? |
| Aged | 35 | 2021 | 215776 | 0.26 | Why? |
| Glucose | 2 | 2017 | 573 | 0.25 | Why? |
| Adult | 41 | 2021 | 244371 | 0.25 | Why? |
| Risk Factors | 25 | 2021 | 71621 | 0.24 | Why? |
| Diastole | 3 | 2019 | 168 | 0.24 | Why? |
| Supine Position | 2 | 2019 | 158 | 0.23 | Why? |
| Aldosterone | 2 | 2019 | 155 | 0.22 | Why? |
| Waist Circumference | 2 | 2018 | 199 | 0.21 | Why? |
| Systole | 2 | 2019 | 252 | 0.21 | Why? |
| Sports | 2 | 2019 | 690 | 0.21 | Why? |
| Atherosclerosis | 2 | 2019 | 768 | 0.21 | Why? |
| Diabetes Mellitus | 4 | 2021 | 8207 | 0.20 | Why? |
| Echocardiography, Doppler | 2 | 2019 | 269 | 0.19 | Why? |
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2018 | 5 | 0.19 | Why? |
| Practice Guidelines as Topic | 5 | 2019 | 15421 | 0.19 | Why? |
| Reticular Formation | 1 | 2018 | 3 | 0.19 | Why? |
| Pressoreceptors | 1 | 2018 | 11 | 0.19 | Why? |
| Hypotension, Orthostatic | 1 | 2019 | 55 | 0.19 | Why? |
| Disease Progression | 6 | 2020 | 13580 | 0.19 | Why? |
| Adrenergic beta-1 Receptor Antagonists | 1 | 2018 | 47 | 0.18 | Why? |
| Glucose Transport Proteins, Facilitative | 1 | 2017 | 5 | 0.18 | Why? |
| Anthropometry | 1 | 2019 | 233 | 0.18 | Why? |
| Sympathomimetics | 1 | 2017 | 22 | 0.18 | Why? |
| Paresis | 1 | 2019 | 77 | 0.18 | Why? |
| Vitamin B 12 Deficiency | 1 | 2018 | 57 | 0.18 | Why? |
| Sex Factors | 10 | 2021 | 11014 | 0.18 | Why? |
| Refractive Errors | 1 | 2017 | 19 | 0.18 | Why? |
| Neurophysiology | 1 | 2018 | 86 | 0.18 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2017 | 5002 | 0.18 | Why? |
| Renal Artery Obstruction | 1 | 2017 | 27 | 0.18 | Why? |
| Treatment Outcome | 10 | 2021 | 51732 | 0.17 | Why? |
| Mental Status and Dementia Tests | 1 | 2018 | 208 | 0.17 | Why? |
| Vascular Remodeling | 1 | 2018 | 99 | 0.17 | Why? |
| Physical Exertion | 1 | 2019 | 176 | 0.17 | Why? |
| Metformin | 2 | 2017 | 640 | 0.17 | Why? |
| Sleep Apnea Syndromes | 2 | 2018 | 282 | 0.17 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.17 | Why? |
| Tomography | 1 | 2019 | 183 | 0.17 | Why? |
| Gout Suppressants | 1 | 2017 | 54 | 0.17 | Why? |
| Autonomic Nervous System Diseases | 1 | 2018 | 67 | 0.17 | Why? |
| Vitamin B 12 | 1 | 2018 | 132 | 0.17 | Why? |
| Albuminuria | 1 | 2018 | 164 | 0.17 | Why? |
| Prevalence | 12 | 2020 | 25773 | 0.16 | Why? |
| Anti-Obesity Agents | 1 | 2017 | 52 | 0.16 | Why? |
| Diet Therapy | 1 | 2017 | 66 | 0.16 | Why? |
| Diuretics | 1 | 2019 | 326 | 0.16 | Why? |
| Sleep Apnea, Obstructive | 1 | 2005 | 668 | 0.16 | Why? |
| Baths | 1 | 2016 | 62 | 0.16 | Why? |
| Double-Blind Method | 2 | 2019 | 5988 | 0.16 | Why? |
| Delayed-Action Preparations | 1 | 2018 | 291 | 0.16 | Why? |
| Work | 1 | 2019 | 342 | 0.16 | Why? |
| Follow-Up Studies | 10 | 2019 | 17020 | 0.15 | Why? |
| Autonomic Nervous System | 1 | 2017 | 148 | 0.15 | Why? |
| Incidence | 10 | 2019 | 25622 | 0.15 | Why? |
| Risk | 4 | 2018 | 5288 | 0.15 | Why? |
| Tachycardia | 1 | 2017 | 239 | 0.15 | Why? |
| Prognosis | 11 | 2020 | 32490 | 0.15 | Why? |
| Calcium Channel Blockers | 1 | 2019 | 367 | 0.15 | Why? |
| Sodium | 1 | 2017 | 309 | 0.15 | Why? |
| Cholesterol, HDL | 1 | 2018 | 439 | 0.14 | Why? |
| Cross-Sectional Studies | 14 | 2021 | 53120 | 0.14 | Why? |
| Arteries | 1 | 2017 | 283 | 0.14 | Why? |
| Bariatric Surgery | 2 | 2017 | 1298 | 0.14 | Why? |
| Nitroprusside | 2 | 2018 | 18 | 0.14 | Why? |
| Erythrocyte Transfusion | 1 | 2018 | 386 | 0.14 | Why? |
| Thrombotic Microangiopathies | 1 | 2018 | 335 | 0.14 | Why? |
| Benzhydryl Compounds | 1 | 2017 | 240 | 0.14 | Why? |
| Consensus | 3 | 2018 | 6345 | 0.14 | Why? |
| Blood Glucose | 3 | 2018 | 3642 | 0.14 | Why? |
| Homeostasis | 1 | 2018 | 582 | 0.13 | Why? |
| Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 284 | 0.13 | Why? |
| Aorta | 1 | 2017 | 355 | 0.13 | Why? |
| Observational Studies as Topic | 2 | 2019 | 1887 | 0.13 | Why? |
| Plaque, Atherosclerotic | 1 | 2017 | 423 | 0.12 | Why? |
| Catheter Ablation | 1 | 2017 | 438 | 0.12 | Why? |
| Overweight | 1 | 2019 | 916 | 0.12 | Why? |
| Fasting | 1 | 2018 | 555 | 0.12 | Why? |
| Leptin | 1 | 2014 | 141 | 0.12 | Why? |
| Cardiology | 2 | 2018 | 2873 | 0.12 | Why? |
| Glycated Hemoglobin A | 2 | 2019 | 1316 | 0.12 | Why? |
| Hypertension, Renovascular | 1 | 2012 | 14 | 0.12 | Why? |
| Cardiomyopathy, Hypertrophic | 1 | 2014 | 193 | 0.12 | Why? |
| Congresses as Topic | 2 | 2019 | 1347 | 0.12 | Why? |
| Opportunistic Infections | 1 | 2019 | 602 | 0.12 | Why? |
| Cytomegalovirus Infections | 1 | 2019 | 667 | 0.12 | Why? |
| Neoplasms | 2 | 2019 | 17251 | 0.12 | Why? |
| Retinal Diseases | 1 | 2017 | 441 | 0.12 | Why? |
| Sulfonylurea Compounds | 1 | 2012 | 79 | 0.11 | Why? |
| Aorta, Abdominal | 1 | 2011 | 50 | 0.11 | Why? |
| Europe | 5 | 2019 | 12702 | 0.11 | Why? |
| Occupational Health | 2 | 2018 | 3965 | 0.11 | Why? |
| Occupations | 1 | 2017 | 733 | 0.11 | Why? |
| Ventricular Dysfunction, Right | 1 | 2018 | 639 | 0.11 | Why? |
| Athletes | 1 | 2019 | 1047 | 0.11 | Why? |
| Sex Characteristics | 1 | 2018 | 1120 | 0.11 | Why? |
| Magnetic Resonance Angiography | 1 | 2011 | 282 | 0.10 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.10 | Why? |
| Stroke | 3 | 2018 | 8839 | 0.10 | Why? |
| Belgium | 1 | 2016 | 2064 | 0.10 | Why? |
| Reproducibility of Results | 4 | 2017 | 11304 | 0.10 | Why? |
| Primary Prevention | 1 | 2017 | 778 | 0.10 | Why? |
| Kidney Diseases | 2 | 2018 | 1434 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| Elasticity Imaging Techniques | 1 | 2011 | 194 | 0.10 | Why? |
| Risk Assessment | 5 | 2021 | 25439 | 0.10 | Why? |
| Hypertension, Pulmonary | 1 | 2018 | 970 | 0.10 | Why? |
| Animals | 4 | 2019 | 78931 | 0.09 | Why? |
| Weight Loss | 1 | 2014 | 826 | 0.09 | Why? |
| Exercise | 2 | 2019 | 6771 | 0.09 | Why? |
| Exercise Therapy | 1 | 2016 | 976 | 0.09 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.08 | Why? |
| Netherlands | 1 | 2016 | 3533 | 0.08 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.08 | Why? |
| Rest | 1 | 2008 | 188 | 0.08 | Why? |
| Analysis of Variance | 2 | 2021 | 950 | 0.08 | Why? |
| Canrenoic Acid | 1 | 2005 | 2 | 0.08 | Why? |
| Adrenergic Fibers | 1 | 2005 | 3 | 0.08 | Why? |
| Internationality | 1 | 2019 | 3297 | 0.08 | Why? |
| Portal System | 1 | 2005 | 9 | 0.08 | Why? |
| Cohort Studies | 6 | 2019 | 36005 | 0.08 | Why? |
| Skin | 1 | 2018 | 2096 | 0.07 | Why? |
| Prospective Studies | 4 | 2018 | 43301 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Sleep | 1 | 2017 | 2695 | 0.07 | Why? |
| Arrhythmias, Cardiac | 1 | 2018 | 2510 | 0.07 | Why? |
| Australia | 1 | 2017 | 6306 | 0.07 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.07 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.06 | Why? |
| Age Factors | 6 | 2021 | 21039 | 0.06 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.06 | Why? |
| Infusions, Intravenous | 1 | 2008 | 1224 | 0.06 | Why? |
| Mineralocorticoid Receptor Antagonists | 1 | 2005 | 203 | 0.06 | Why? |
| Peroneal Nerve | 2 | 2017 | 13 | 0.06 | Why? |
| Hypoxia | 1 | 2018 | 3626 | 0.06 | Why? |
| Coronary Artery Disease | 1 | 2018 | 2570 | 0.06 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.06 | Why? |
| Antirheumatic Agents | 1 | 2018 | 3023 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2019 | 3550 | 0.06 | Why? |
| Occupational Stress | 1 | 2017 | 2044 | 0.06 | Why? |
| Liver | 1 | 2017 | 4007 | 0.06 | Why? |
| Time Factors | 4 | 2019 | 31397 | 0.06 | Why? |
| Germany | 1 | 2017 | 9196 | 0.06 | Why? |
| Population Surveillance | 2 | 2017 | 4967 | 0.06 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.05 | Why? |
| Primary Health Care | 1 | 2019 | 4839 | 0.05 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.05 | Why? |
| Myography | 1 | 2018 | 6 | 0.05 | Why? |
| Phenylephrine | 1 | 2018 | 20 | 0.05 | Why? |
| Ganciclovir | 1 | 2019 | 97 | 0.05 | Why? |
| Dose-Response Relationship, Drug | 1 | 2008 | 3776 | 0.04 | Why? |
| Acute Kidney Injury | 1 | 2018 | 5762 | 0.04 | Why? |
| Microelectrodes | 1 | 2017 | 15 | 0.04 | Why? |
| Journalism, Medical | 1 | 2018 | 50 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.04 | Why? |
| Serbia | 1 | 2018 | 227 | 0.04 | Why? |
| Stress, Psychological | 1 | 2021 | 10231 | 0.04 | Why? |
| Ultrasonography | 3 | 2018 | 4409 | 0.04 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.04 | Why? |
| United Kingdom | 1 | 2018 | 18046 | 0.04 | Why? |
| Organ Size | 1 | 2018 | 384 | 0.04 | Why? |
| Brain Stem | 1 | 2018 | 131 | 0.04 | Why? |
| Endothelin-1 | 1 | 2016 | 69 | 0.04 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.04 | Why? |
| Intensive Care Units | 2 | 2020 | 29594 | 0.04 | Why? |
| Hepatitis B | 1 | 2005 | 888 | 0.04 | Why? |
| Registries | 1 | 2017 | 12327 | 0.04 | Why? |
| Observer Variation | 1 | 2019 | 622 | 0.04 | Why? |
| Kidney Function Tests | 1 | 2018 | 520 | 0.04 | Why? |
| Death, Sudden | 1 | 2018 | 160 | 0.04 | Why? |
| Glucose Tolerance Test | 1 | 2017 | 238 | 0.04 | Why? |
| Renin | 1 | 2016 | 167 | 0.04 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.04 | Why? |
| Review Literature as Topic | 1 | 2019 | 387 | 0.04 | Why? |
| Multimorbidity | 1 | 2020 | 703 | 0.04 | Why? |
| Systems Biology | 1 | 2017 | 320 | 0.04 | Why? |
| Vasodilator Agents | 1 | 2018 | 344 | 0.04 | Why? |
| United States | 2 | 2019 | 46150 | 0.04 | Why? |
| Epinephrine | 1 | 2016 | 323 | 0.03 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.03 | Why? |
| Vasoconstrictor Agents | 1 | 2018 | 714 | 0.03 | Why? |
| Sensitivity and Specificity | 2 | 2012 | 22971 | 0.03 | Why? |
| Gastroenteritis | 1 | 2019 | 489 | 0.03 | Why? |
| Fluid Therapy | 1 | 2018 | 628 | 0.03 | Why? |
| Hepatitis C | 1 | 2005 | 1514 | 0.03 | Why? |
| Cytomegalovirus | 1 | 2019 | 600 | 0.03 | Why? |
| Liver Cirrhosis | 1 | 2005 | 1810 | 0.03 | Why? |
| Survival Rate | 2 | 2020 | 9206 | 0.03 | Why? |
| Exercise Test | 1 | 2019 | 911 | 0.03 | Why? |
| Respiration | 1 | 2018 | 729 | 0.03 | Why? |
| Elastic Modulus | 1 | 2011 | 22 | 0.03 | Why? |
| History, 20th Century | 1 | 2018 | 1282 | 0.03 | Why? |
| Pulsatile Flow | 1 | 2011 | 123 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2017 | 1262 | 0.03 | Why? |
| China | 1 | 2018 | 50654 | 0.03 | Why? |
| History, 21st Century | 1 | 2018 | 1849 | 0.03 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.03 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2019 | 10649 | 0.03 | Why? |
| Nitric Oxide | 1 | 2016 | 769 | 0.02 | Why? |
| Vitamins | 1 | 2018 | 1208 | 0.02 | Why? |
| Frailty | 1 | 2021 | 1432 | 0.02 | Why? |
| Smoking | 1 | 2021 | 3358 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.02 | Why? |
| Survivors | 1 | 2019 | 2619 | 0.02 | Why? |
| Employment | 1 | 2018 | 1754 | 0.02 | Why? |
| Equipment Design | 1 | 2017 | 3095 | 0.02 | Why? |
| Venous Pressure | 1 | 2005 | 5 | 0.02 | Why? |
| Chronic Disease | 1 | 2021 | 5139 | 0.02 | Why? |
| Liver Circulation | 1 | 2005 | 12 | 0.02 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Research | 1 | 2018 | 2115 | 0.02 | Why? |
| Periodicals as Topic | 1 | 2018 | 1492 | 0.02 | Why? |
| Hepatic Veins | 1 | 2005 | 54 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Logistic Models | 1 | 2019 | 9089 | 0.02 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Esophageal and Gastric Varices | 1 | 2005 | 117 | 0.02 | Why? |
| Socioeconomic Factors | 1 | 2021 | 8495 | 0.02 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.01 | Why? |
| Retrospective Studies | 3 | 2019 | 105322 | 0.01 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.01 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.01 | Why? |
| Quality of Life | 1 | 2019 | 9820 | 0.01 | Why? |
| Pregnancy | 1 | 2019 | 23879 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Child | 1 | 2018 | 70012 | 0.01 | Why? |
| Antiviral Agents | 1 | 2019 | 41703 | 0.00 | Why? |